A study emphasized the importance of muscarinic M1 and M4 receptors in treating schizophrenia, with new medications like KarXT and emraclidine targeting these receptors as promising alternatives to traditional antipsychotics. Advances in neuroimaging and TAAR1 agonists research indicate a range of potential treatments for schizophrenia. The development of CHRMs-targeted drugs marks a major progress in treatment, highlighting the need for ongoing research into schizophrenia’s molecular pathology.

Reference: Dean B, Bakker G, Ueda HR, Tobin AB, et al. A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Front Cell Neurosci. 2023 Feb 22;17:1124333. doi: 10.3389/fncel.2023.1124333. PMID: 36909280; PMCID: PMC9992992.